PDEGX Performance — PGIM Target Date 2025 Fund, Class R4
Data updated: 2026-10-13
PDEGX returned +5.92% year to date and +11.70% over one year to Jul 2026. Annualised returns are +9.57% over 3 years and +5.01% over 5 years. The fund trailed its Target-Date category average: $100 invested three years ago grew to $132, against $146 for the category, and to $112 over one year, against $116. Volatility over the past three years was 6.92% a year. In the 12 months to Jul 2026 the fund lost a net $9.5M, and assets reached $41.34M.
PDEGX Growth of $100
What $100 invested in PGIM Target Date 2025 Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Target-Date category average over the same months.
| Period | PDEGX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $112 | $116 |
| 3 years (Aug 2023 – Jul 2026) | $132 | $146 |
| 5 years (Aug 2021 – Jul 2026) | $128 | $142 |
| Since data start (Aug 2019 – Jul 2026) | $160 | $186 |
PDEGX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +5.92% |
| 1 year | +11.70% |
| 3 years (annualised) | +9.57% |
| 5 years (annualised) | +5.01% |
PDEGX Annual Returns
Calendar-year total returns of PGIM Target Date 2025 Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +5.92% |
| 2025 | +11.76% |
| 2024 | +8.06% |
| 2023 | +10.97% |
| 2022 | −12.54% |
| 2021 | +12.48% |
| 2020 | +9.04% |
| 2019 (Aug–Dec) | +4.99% |
PDEGX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.8% | +1.7% | −3.0% | +4.4% | +1.3% | −0.2% | −0.1% | — | — | — | — | — |
| 2025 | +1.9% | +1.0% | −1.3% | +0.1% | +1.8% | +2.4% | +0.1% | +2.1% | +1.6% | +0.9% | +0.8% | −0.1% |
| 2024 | +0.2% | +1.0% | +2.1% | −2.6% | +2.9% | +0.9% | +1.9% | +1.8% | +1.7% | −2.0% | +2.3% | −2.2% |
| 2023 | +4.5% | −2.4% | +1.9% | +0.8% | −1.4% | +2.6% | +1.8% | −1.3% | −2.9% | −1.8% | +5.4% | +3.7% |
| 2022 | −2.5% | −0.8% | +0.7% | −4.5% | 0.0% | −5.6% | +5.3% | −3.0% | −7.2% | +3.3% | +4.6% | −2.7% |
| 2021 | −0.2% | +1.0% | +1.5% | +2.9% | +1.2% | +0.9% | +1.7% | +0.9% | −2.2% | +2.9% | −1.1% | +2.4% |
| 2020 | +0.2% | −3.6% | −9.1% | +6.0% | +3.0% | +2.0% | +3.0% | +2.8% | −1.7% | −1.4% | +6.0% | +2.6% |
| 2019 | — | — | — | — | — | — | — | +0.1% | +0.8% | +1.3% | +1.1% | +1.5% |
PDEGX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 6.92%
- 3-year Sharpe ratio: 0.73 (vs 4.5% risk-free rate)
- Best month: +5.38% (Nov 2023)
- Worst month: −3.04% (Mar 2026)
PDEGX Fund Flows
Monthly money in and out of PGIM Target Date 2025 Fund, from SEC Form N-PORT.
- 12-month net flow: −$9.5M
- 12-month gross sales (incl. reinvestments): $5.9M
- Sales ÷ redemptions: 0.38×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $297K | $326K | −$28K |
| Jun 2026 | $83K | $338K | −$256K |
| May 2026 | $135K | $6.7M | −$6.6M |
| Apr 2026 | $309K | $1.3M | −$998K |
| Mar 2026 | $254K | $1.3M | −$1.0M |
| Feb 2026 | $205K | $550K | −$345K |
| Jan 2026 | $115K | $1.5M | −$1.4M |
| Dec 2025 | $3.1M | $610K | $2.5M |
| Nov 2025 | $109K | $307K | −$198K |
| Oct 2025 | $306K | $1.5M | −$1.1M |
| Sep 2025 | $857K | $556K | $301K |
| Aug 2025 | $115K | $420K | −$305K |
PDEGX Assets Under Management
Net assets of PGIM Target Date 2025 Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $41.34M |
| 2026-04-30 | $47.74M |
| 2026-01-30 | $48.71M |
| 2025-10-31 | $49.16M |
| 2025-07-31 | $48.03M |
| 2025-04-30 | $48.95M |
| 2025-01-31 | $50.44M |
| 2024-10-31 | $49.83M |
| 2024-07-31 | $48.14M |
| 2024-04-30 | $46.63M |
| 2024-01-31 | $48.39M |
| 2023-10-31 | $55.18M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.